NASDAQ:BNTX

ROSEN, A RANKED AND LEADING FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action – BNTX

Retrieved on: 
Thursday, February 8, 2024
Titan, COVID-19, Pfizer–BioNTech COVID-19 vaccine, Pfizer, Advertising, Class, BioNTech, Risk, BNTX, Court

WHAT TO DO NEXT: To join the BioNTech class action, go to https://rosenlegal.com/submit-form/?case_id=21850 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the BioNTech class action, go to https://rosenlegal.com/submit-form/?case_id=21850 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

DEADLINE ALERT for MSS, ASRT, DADA, BNTX: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Thursday, February 8, 2024
The Company, Investment, COVID-19, Pfizer–BioNTech COVID-19 vaccine, Suite, Sale, Class, BioNTech, Supermarket, Risk, Marketing, Spectrum, EB-5, Telephone, Pfizer, Law

BENSALEM, Pa., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • BENSALEM, Pa., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at 888-638-4847 or by email to [email protected] .
  • Law Offices of Howard G. Smith

SHAREHOLDER ALERT: Levi & Korsinsky Notifies BioNTech SE(BNTX) Investors of a Class Action Lawsuit and Upcoming Deadline

Retrieved on: 
Thursday, February 8, 2024
CLASS, COVID-19, Pfizer–BioNTech COVID-19 vaccine, BioNTech, Risk, LLP, Telephone, BNTX, NEXT, Court, COST, Cryptocurrency

NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in BioNTech SE ("BioNTech" or the "Company") (NASDAQ: BNTX) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in BioNTech SE ("BioNTech" or the "Company") (NASDAQ: BNTX) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of BioNTech investors who were adversely affected by alleged securities fraud between March 30, 2022 and October 13, 2023.
  • Follow the link below to get more information and be contacted by a member of our team:
    BNTX investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

BIONTECH INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioNTech To Contact Him Directly To Discuss Their Options

Retrieved on: 
Thursday, February 8, 2024
Third Bridge, Vaccination, ADS, News, Food, The Company, Advertising, Woman, COVID-19, Pfizer–BioNTech COVID-19 vaccine, Cost, BioNTech, Omicron, EUR, Risk, COVID, LLP, Research, BNTX, Court, Pharmaceutical industry

NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX) and reminds investors of the March 12, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The Company attributed the result, in part, to the "dynamic" development of the pandemic, which "caus[ed] a re-phasing of orders and .
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding BioNTech’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ).

DEADLINE ALERT for DADA, BNTX, and CMI: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Thursday, February 8, 2024
Nexus, The Company, Investment, COVID-19, Pfizer–BioNTech COVID-19 vaccine, Suite, Defendant, BioNTech, Risk, Marketing, Pfizer, Law, Security (finance)

LOS ANGELES, Feb. 08, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • LOS ANGELES, Feb. 08, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected] .
  • The Law Offices of Frank R. Cruz, Los Angeles

BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs  

Retrieved on: 
Thursday, February 8, 2024
Acute leukemia, Therapy, BNTX, Patient, BioNTech, Entrepreneurship, CLDN6, American depositary receipt, Cooley LLP, Cancer, LLP, Pharmaceutical industry

In connection with the strategic collaboration, the companies entered into a license and option agreement and a securities purchase agreement.

Key Points: 
  • In connection with the strategic collaboration, the companies entered into a license and option agreement and a securities purchase agreement.
  • “The collaboration with Autolus enables us to expand our BNT211 program into trials for multiple cancer indications in a cost-efficient way.
  • "Furthermore, this collaboration grants us access to Autolus' precise cell targeting tools to further support BioNTech’s development of in vivo cell therapy and antibody-drug conjugate candidates."
  • “We see a remarkable opportunity to leverage our core capabilities, accelerate pipeline programs, realize cost-efficiencies and expand opportunities beyond autologous cell therapies,” said Dr. Christian Itin, Chief Executive Officer of Autolus.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Mercury Systems, Onsemi, BioNTech, and BioVie and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, February 7, 2024
Pfizer–BioNTech COVID-19 vaccine, Mercury Systems, Onsemi, EPS, Silicon carbide, COVID-19, Pfizer, Growth, CFO, GAAP, OSI, GCP, Clinical trial, News, BNTX, Patient, Good clinical practice, Mercury, Tesla, Inc., P.C, Complaint, FDA, POC, EV, BioNTech, Food, LTSA, Silicon, Risk, Acquisition, MRCY, Defendant, Sale, Accreditation, Small business, Glass house, Pharmaceutical industry

Mercury Systems is a technology company that produces component modules and subsystems for the aerospace and defense industries.

Key Points: 
  • Mercury Systems is a technology company that produces component modules and subsystems for the aerospace and defense industries.
  • On this news, the price of Mercury Systems common stock fell more than 17%, the complaint alleges.
  • The Mercury Systems class action lawsuit alleges that on this news, the price of Mercury Systems common stock fell nearly 10%.
  • For more information on the BioVie class action go to: https://bespc.com/cases/BIVI

BNTX INVESTOR NEWS: Shareholders Should Contact Robbins LLP for Information About the Securities Fraud Class Action Against BioNTech SE

Retrieved on: 
Tuesday, February 6, 2024
Pfizer–BioNTech COVID-19 vaccine, Pfizer, COVID-19, ADS, News, BNTX, BioNTech, Biotechnology, Risk, Infection, LLP, Cancer, Complaint, Person, Pharmaceutical industry

Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and October 13, 2023.

Key Points: 
  • Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and October 13, 2023.
  • BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against BioNTech SE.
  • Shareholders who want to act as lead plaintiff for the class should contact Robbins LLP.

BIONTECH SE (NASDAQ: BNTX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against BioNTech SE

Retrieved on: 
Tuesday, February 6, 2024
Pfizer–BioNTech COVID-19 vaccine, Pfizer, COVID-19, ADS, News, BNTX, BioNTech, Biotechnology, District court, Risk, Advertising, Defendant, Complaint, Infection, Cancer, Court, Security (finance)

Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX) between March 30, 2022 and October 13, 2023, inclusive (the “Class Period”).

Key Points: 
  • Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX) between March 30, 2022 and October 13, 2023, inclusive (the “Class Period”).
  • If you wish to serve as lead plaintiff, you must move the Court no later than March 12, 2024.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioNTech SE (BNTX)

Retrieved on: 
Monday, February 5, 2024
Pfizer–BioNTech COVID-19 vaccine, COVID-19, Pfizer, News, BNTX, COVID, GPM, BioNTech, Risk, The Company, Defendant, Suite, Court, Forecasting, Pharmaceutical industry

On this news, BioNTech’s stock price fell $13.81, or 7.5%, to close at $169.30 per share on August 8, 2022, thereby injuring investors.

Key Points: 
  • On this news, BioNTech’s stock price fell $13.81, or 7.5%, to close at $169.30 per share on August 8, 2022, thereby injuring investors.
  • On this news, BioNTech’s stock price fell $4.60, or 3.6%, to close at $123.60 per share on March 27, 2023.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles